Advertisement

Special Considerations: Treatment of Pediatric Uveitis

  • Himanshu K. Banda
  • Steven Yeh
Chapter

Abstract

Pediatric uveitis is a significant cause of ocular morbidity and poses diagnostic and treatment dilemmas to ophthalmologists. The spectrum of clinical presentation, difficulty in examination of children, and lifetime burden of vision loss without adequate treatment are the main challenges in management of pediatric uveitis. While infectious and noninfectious, systemic autoimmune conditions may be associated with pediatric uveitis, juvenile idiopathic arthritis remains the most common associated disease condition. Coordination with pediatric rheumatologists and primary care physicians is important to provide comprehensive, multidisciplinary care. While traditional disease-modifying antirheumatic drugs such as methotrexate remain a mainstay for noninfectious pediatric uveitis to avoid complications of topical ophthalmic corticosteroids, the biologic agents, notably the anti-tumor necrosis factor-alpha inhibitors adalimumab and infliximab, have been increasingly used given their benefit in the control of ocular inflammation. This chapter summarizes the common causes of pediatric uveitis and the management approach to the spectrum of disease entities.

Keywords

Pediatric uveitis Juvenile idiopathic arthritis Band keratopathy Intermediate uveitis Pars planitis Adalimumab Infliximab Methotrexate Prednisolone acetate 

References

  1. 1.
    Cunningham ET Jr. Uveitis in children. Ocul Immunol Inflamm. 2000;8:251–61.CrossRefGoogle Scholar
  2. 2.
    Suhler EB, Lloyd MD, Choi D, et al. Incidence and prevalence of uveitis in Veterans Affairs Medical Centers of the Pacific Northwest. Am J Ophthalmol. 2008;146:890–6.CrossRefGoogle Scholar
  3. 3.
    Zierhut M, Michels H, Stubiger N, Besch D, Deuter C, Heiligenhaus A. Uveitis in children. Int Ophthalmol Clin. 2005;45:135–56.CrossRefGoogle Scholar
  4. 4.
    Levy-Clarke GA, Nussenblatt RB, Smith JA. Management of chronic pediatric uveitis. Curr Opin Ophthalmol. 2005;16:281–8.CrossRefGoogle Scholar
  5. 5.
    Malinowski SM, Pulido JS, Folk JC. Long-term visual outcome and complications associated with pars planitis. Ophthalmology. 1993;100:818–24.CrossRefGoogle Scholar
  6. 6.
    Rosenberg KD, Feuer WJ, Davis JL. Ocular complications of pediatric uveitis. Ophthalmology. 2004;111:2299–306.CrossRefGoogle Scholar
  7. 7.
    Nagpal A, Leigh JF, Acharya NR. Epidemiology of uveitis in children. Int Ophthalmol Clin. 2008;48:1–7.CrossRefGoogle Scholar
  8. 8.
    Deschenes J, Murray PI, Rao NA, Nussenblatt RB. International Uveitis Study G. International Uveitis Study Group (IUSG): clinical classification of uveitis. Ocul Immunol Inflamm. 2008;16:1–2.CrossRefGoogle Scholar
  9. 9.
    Wentworth BA, Freitas-Neto CA, Foster CS. Management of pediatric uveitis. F1000Prime Rep. 2014;6:41.CrossRefGoogle Scholar
  10. 10.
    Michels H, Schuchmann L, Truckenbrodt H, Renz K. Rheumatic iridocyclitis in childhood – differentiation on the basis of clinical and immunological parameters. Klin Padiatr. 1982;194:104–8.CrossRefGoogle Scholar
  11. 11.
    Thorne JE, Woreta FA, Dunn JP. Risk of cataract development among children with juvenile idiopathic arthritis-related uveitis treated with topical corticosteroids. Ophthalmology. 2010;117:1436–41.CrossRefGoogle Scholar
  12. 12.
    Slabaugh MA, Herlighy E, Ongchin S, van Gelder RN. Efficacy and potential complications of difluprednate use for pediatric uveitis. Am J Ophthalmol. 2012;153:932–8.CrossRefGoogle Scholar
  13. 13.
    Buchman AL. Side effects of corticosteroid therapy. J Clin Gastroenterol. 2001;33:289–94.CrossRefGoogle Scholar
  14. 14.
    Sood AB, Angeles-Han ST. An update on the treatment of pediatric chronic non-infectious uveitis. Curr Treatm Opt Rheumatol. 2017;3:1–16.CrossRefGoogle Scholar
  15. 15.
    Smith JA, Mackensen F, Sen HN, et al. Epidemiology and course of disease in childhood uveitis. Ophthalmology. 2009;116:1544–51, 51.e1CrossRefGoogle Scholar
  16. 16.
    Petty RE, Southwood TR, Baum J, et al. Revision of the proposed classification criteria for juvenile idiopathic arthritis: Durban, 1997. J Rheumatol. 1998;25:1991–4.PubMedGoogle Scholar
  17. 17.
    Chia A, Lee V, Graham EM, Edelsten C. Factors related to severe uveitis at diagnosis in children with juvenile idiopathic arthritis in a screening program. Am J Ophthalmol. 2003;135:757–62.CrossRefGoogle Scholar
  18. 18.
    Wolf MD, Lichter PR, Ragsdale CG. Prognostic factors in the uveitis of juvenile rheumatoid arthritis. Ophthalmology. 1987;94:1242–8.CrossRefGoogle Scholar
  19. 19.
    Kotaniemi K, Kautiainen H, Karma A, Aho K. Occurrence of uveitis in recently diagnosed juvenile chronic arthritis: a prospective study. Ophthalmology. 2001;108:2071–5.CrossRefGoogle Scholar
  20. 20.
    Zierhut M, Doycheva D, Biester S, Stubiger N, Kummerle-Deschner J, Deuter C. Therapy of uveitis in children. Int Ophthalmol Clin. 2008;48:131–52.CrossRefGoogle Scholar
  21. 21.
    Armaly MF. Statistical attributes of the steroid hypertensive response in the clinically normal eye. I. The demonstration of three levels of response. Invest Ophthalmol. 1965;4:187–97.PubMedGoogle Scholar
  22. 22.
    Hawkins MJ, Dick AD, Lee RJ, et al. Managing juvenile idiopathic arthritis-associated uveitis. Surv Ophthalmol. 2016;61:197–210.CrossRefGoogle Scholar
  23. 23.
    Heiligenhaus A, Michels H, Schumacher C, et al. Evidence-based, interdisciplinary guidelines for anti-inflammatory treatment of uveitis associated with juvenile idiopathic arthritis. Rheumatol Int. 2012;32:1121–33.CrossRefGoogle Scholar
  24. 24.
    Simonini G, Paudyal P, Jones GT, Cimaz R, Macfarlane GJ. Current evidence of methotrexate efficacy in childhood chronic uveitis: a systematic review and meta-analysis approach. Rheumatology (Oxford). 2013;52:825–31.CrossRefGoogle Scholar
  25. 25.
    Sijssens KM, Rothova A, Van De Vijver DA, Stilma JS, De Boer JH. Risk factors for the development of cataract requiring surgery in uveitis associated with juvenile idiopathic arthritis. Am J Ophthalmol. 2007;144:574–9.CrossRefGoogle Scholar
  26. 26.
    Bou R, Adan A, Borras F, et al. Clinical management algorithm of uveitis associated with juvenile idiopathic arthritis: interdisciplinary panel consensus. Rheumatol Int. 2015;35:777–85.CrossRefGoogle Scholar
  27. 27.
    Amin RM, Miserocchi E, Thorne JE, Hornbeak D, Jabs DA, Zierhut M. Treatment options for juvenile idiopathic arthritis (JIA) associated uveitis. Ocul Immunol Inflamm. 2016;24:81–90.CrossRefGoogle Scholar
  28. 28.
    Bichler J, Benseler SM, Krumrey-Langkammerer M, Haas JP, Hugle B. Leflunomide is associated with a higher flare rate compared to methotrexate in the treatment of chronic uveitis in juvenile idiopathic arthritis. Scand J Rheumatol. 2015;44:280–3.CrossRefGoogle Scholar
  29. 29.
    Ramanan AV, Dick AD, Jones AP, et al. Adalimumab plus methotrexate for uveitis in juvenile idiopathic arthritis. N Engl J Med. 2017;376:1637–46.CrossRefGoogle Scholar
  30. 30.
    Correll CK, Bullock DR, Cafferty RM, Vehe RK. Safety of weekly adalimumab in the treatment of juvenile idiopathic arthritis and pediatric chronic uveitis. Clin Rheumatol. 2018;37:549–53.CrossRefGoogle Scholar
  31. 31.
    Tambralli A, Beukelman T, Weiser P, Atkinson TP, Cron RQ, Stoll ML. High doses of infliximab in the management of juvenile idiopathic arthritis. J Rheumatol. 2013;40:1749–55.CrossRefGoogle Scholar
  32. 32.
    Smith JA, Thompson DJ, Whitcup SM, et al. A randomized, placebo-controlled, double-masked clinical trial of etanercept for the treatment of uveitis associated with juvenile idiopathic arthritis. Arthritis Rheum. 2005;53:18–23.CrossRefGoogle Scholar
  33. 33.
    Calvo-Rio V, Santos-Gomez M, Calvo I, et al. Anti-interleukin-6 receptor tocilizumab for severe juvenile idiopathic arthritis-associated uveitis refractory to anti-tumor necrosis factor therapy: a multicenter study of twenty-five patients. Arthritis Rheumatol. 2017;69:668–75.CrossRefGoogle Scholar
  34. 34.
    Tappeiner C, Mesquida M, Adan A. Evidence for tocilizumab as a treatment option in refractory uveitis associated with juvenile idiopathic arthritis. J Rheumatol. 2016;43:2183–8.CrossRefGoogle Scholar
  35. 35.
    Mesquida M, Molins B, Llorenc V, et al. Twenty-four month month follow-up of tocilizumab therapy for refractory uveitis-related macular edema. Retina. 2018;38:1361–70.CrossRefGoogle Scholar
  36. 36.
    Tappeiner C, Miserocchi E, Bodaghi B, et al. Abatacept in the treatment of severe, longstanding, and refractory uveitis associated with juvenile idiopathic arthritis. J Rheumatol. 2015;42:706–11.CrossRefGoogle Scholar
  37. 37.
    Adrovic A, Barut K, Sahin S, Kasapcopur O. Juvenile spondyloarthropathies. Curr Rheumatol Rep. 2016;18:55.CrossRefGoogle Scholar
  38. 38.
    van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum. 1984;27:361–8.CrossRefGoogle Scholar
  39. 39.
    Hoover DL, Khan JA, Giangiacomo J. Pediatric ocular sarcoidosis. Surv Ophthalmol. 1986;30:215–28.CrossRefGoogle Scholar
  40. 40.
    Jasper PL, Denny FW. Sarcoidosis in children. With special emphasis on the natural history and treatment. J Pediatr. 1968;73:499–512.CrossRefGoogle Scholar
  41. 41.
    Weinreb RN. Diagnosing sarcoidosis by transconjunctival biopsy of the lacrimal gland. Am J Ophthalmol. 1984;97:573–6.CrossRefGoogle Scholar
  42. 42.
    Rodriguez GE, Shin BC, Abernathy RS, Kendig EL Jr. Serum angiotensin-converting enzyme activity in normal children and in those with sarcoidosis. J Pediatr. 1981;99:68–72.CrossRefGoogle Scholar
  43. 43.
    Gedalia A, Molina JF, Ellis GS Jr, Galen W, Moore C, Espinoza LR. Low-dose methotrexate therapy for childhood sarcoidosis. J Pediatr. 1997;130:25–9.CrossRefGoogle Scholar
  44. 44.
    Lopalco G, Fabiani C, Sota J, et al. IL-6 blockade in the management of non-infectious uveitis. Clin Rheumatol. 2017;36:1459–69.CrossRefGoogle Scholar
  45. 45.
    Lu L, Shen M, Jiang D, et al. Blau syndrome with good responses to tocilizumab: a case report and focused literature review. Semin Arthritis Rheum. 2018;47:727–31.CrossRefGoogle Scholar
  46. 46.
    Mackensen F, Smith JR, Rosenbaum JT. Enhanced recognition, treatment, and prognosis of tubulointerstitial nephritis and uveitis syndrome. Ophthalmology. 2007;114:995–9.CrossRefGoogle Scholar
  47. 47.
    Mackensen F, Billing H. Tubulointerstitial nephritis and uveitis syndrome. Curr Opin Ophthalmol. 2009;20:525–31.CrossRefGoogle Scholar
  48. 48.
    Gion N, Stavrou P, Foster CS. Immunomodulatory therapy for chronic tubulointerstitial nephritis-associated uveitis. Am J Ophthalmol. 2000;129:764–8.CrossRefGoogle Scholar
  49. 49.
    Jabs DA, Nussenblatt RB, Rosenbaum JT, Standardization of Uveitis Nomenclature Working G. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol. 2005;140:509–16.CrossRefGoogle Scholar
  50. 50.
    Pederson JE, Kenyon KR, Green WR, Maumenee AE. Pathology of pars planitis. Am J Ophthalmol. 1978;86:762–74.CrossRefGoogle Scholar
  51. 51.
    Nussenblatt RB, Whitcup SM, Palestine AG. Uveitis: fundamentals and clinical practice. 2nd ed. St. Louis: Mosby; 1996.Google Scholar
  52. 52.
    Tang WM, Pulido JS, Eckels DD, Han DP, Mieler WF, Pierce K. The association of HLA-DR15 and intermediate uveitis. Am J Ophthalmol. 1997;123:70–5.CrossRefGoogle Scholar
  53. 53.
    Mikkila HO, Seppala IJ, Viljanen MK, Peltomaa MP, Karma A. The expanding clinical spectrum of ocular lyme borreliosis. Ophthalmology. 2000;107:581–7.CrossRefGoogle Scholar
  54. 54.
    Karma A, Seppala I, Mikkila H, Kaakkola S, Viljanen M, Tarkkanen A. Diagnosis and clinical characteristics of ocular Lyme borreliosis. Am J Ophthalmol. 1995;119:127–35.CrossRefGoogle Scholar
  55. 55.
    Rosenbaum JT, Rahn DW. Prevalence of Lyme disease among patients with uveitis. Am J Ophthalmol. 1991;112:462–3.CrossRefGoogle Scholar
  56. 56.
    Wormser GP, Dattwyler RJ, Shapiro ED, et al. The clinical assessment, treatment, and prevention of Lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis. 2006;43:1089–134.CrossRefGoogle Scholar
  57. 57.
    Giles CL. Uveitis in childhood – part III. Posterior. Ann Ophthalmol. 1989;21:23–8.PubMedGoogle Scholar
  58. 58.
    Nussenblatt RB, Belfort R Jr. Ocular toxoplasmosis. An old disease revisited. JAMA. 1994;271:304–7.CrossRefGoogle Scholar
  59. 59.
    Wong SY, Remington JS. Toxoplasmosis in pregnancy. Clin Infect Dis. 1994;18:853–61; quiz 62.CrossRefGoogle Scholar
  60. 60.
    Schantz PM, Glickman LT. Toxocaral visceral larva migrans. N Engl J Med. 1978;298:436–9.CrossRefGoogle Scholar
  61. 61.
    Schantz PM. Toxocara larva migrans now. Am J Trop Med Hyg. 1989;41:21–34.CrossRefGoogle Scholar
  62. 62.
    Shields JA, Lerner HA, Felberg NT. Aqueous cytology and enzymes in nematode endophthalmitis. Am J Ophthalmol. 1977;84:319–22.CrossRefGoogle Scholar
  63. 63.
    Dinning WJ, Gillespie SH, Cooling RJ, Maizels RM. Toxocariasis: a practical approach to management of ocular disease. Eye (Lond). 1988;2(Pt 5):580–2.CrossRefGoogle Scholar
  64. 64.
    Shields JA. Ocular toxocariasis. A review. Surv Ophthalmol. 1984;28:361–81.CrossRefGoogle Scholar
  65. 65.
    Fitzgerald CR, Rubin ML. Intraocular parasite destroyed by photocoagulation. Arch Ophthalmol. 1974;91:162–4.CrossRefGoogle Scholar
  66. 66.
    Krause I, Uziel Y, Guedj D, et al. Childhood Behcet’s disease: clinical features and comparison with adult-onset disease. Rheumatology (Oxford). 1999;38:457–62.CrossRefGoogle Scholar
  67. 67.
    Treudler R, Orfanos CE, Zouboulis CC. Twenty-eight cases of juvenile-onset Adamantiades-Behcet disease in Germany. Dermatology. 1999;199:15–9.CrossRefGoogle Scholar
  68. 68.
    Kone-Paut I. Behcet’s disease in children, an overview. Pediatr Rheumatol Online J. 2016;14:10.CrossRefGoogle Scholar
  69. 69.
    Soheilian M, Aletaha M, Yazdani S, Dehghan MH, Peyman GA. Management of pediatric Vogt-Koyanagi-Harada (VKH)-associated panuveitis. Ocul Immunol Inflamm. 2006;14:91–8.CrossRefGoogle Scholar
  70. 70.
    Jeroudi A, Angeles-Han ST, Yeh S. Efficacy of adalimumab for pediatric Vogt-Koyanagi-Harada syndrome. Ophthalmic Surg Lasers Imaging Retina. 2014;45(4):332–4.CrossRefGoogle Scholar
  71. 71.
    Khalifa YM, Bailony MR, Acharya NR. Treatment of pediatric Vogt-Koyanagi-Harada syndrome with infliximab. Ocul Immunol Inflamm. 2010;18(3):218–22.CrossRefGoogle Scholar
  72. 72.
    Kim JB, Jeroudi A, Angeles-Han ST, et al. Adalimumab for pediatric sympathetic ophthalmia. JAMA Ophthalmol. 2014;132(8):1022–4.CrossRefGoogle Scholar
  73. 73.
    Gupta SR, Phan IT, Suhler EB. Successful treatment of refractory sympathetic ophthalmic in a child with infliximab. Arch Ophthalmol. 2011;129:250–2.CrossRefGoogle Scholar
  74. 74.
    Regulations requiring manufacturers to assess the safety and effectiveness of new drugs and biological products in pediatric patients – FDA. Final rule. Fed Regist 1998;63:66631–66672.Google Scholar
  75. 75.
    Interlandi E, Leccese P, Olivieri I, Latanza L. Adalimumab for treatment of severe Behçet’s uveitis: a retrospective long-term follow-up study. Clin Exp Rheumatol. 2014;32(4 Suppl 84):S58–62.PubMedGoogle Scholar
  76. 76.
    Calvo-Río V, Blanco R, Beltrán E, et al. Anti-TNF-α therapy in patients with refractory uveitis due to Behçet’s disease: a 1-year follow-up study of 124 patients. Rheumatology (Oxford). 2014;53(12):2223–31.CrossRefGoogle Scholar
  77. 77.
    Vallet H, Seve P, Biard L, et al. Infliximab versus adalimumab in the treatment of refractory inflammatory uveitis: a multicenter study from the French Uveitis Network. Arthritis Rheumatol. 2016;68(6):1522–30.CrossRefGoogle Scholar
  78. 78.
    Papo M, Bielefeld P, Vallet H, et al. Tocilizumab in severe and refractory non-infectious uveitis. Clin Exp Rheumatol. 2014;32(4 Suppl 84):S75–9.PubMedGoogle Scholar
  79. 79.
    Marrani E, Paganelli V, de Libero C, et al. Long-term efficacy of abatacept in pediatric patients with idiopathic uveitis: a case series. Graefes Arch Clin Exp Ophthalmol. 2015;253(10):1813–6.CrossRefGoogle Scholar
  80. 80.
    Lin P, Suhler EB, Rosenbaum JT. The future of uveitis treatment. Ophthalmology. 2014;121(1):365–76.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Himanshu K. Banda
    • 1
  • Steven Yeh
    • 1
  1. 1.Department of Ophthalmology, Uveitis and Vasculitis Service, Emory Eye Center, Emory University School of MedicineAtlantaUSA

Personalised recommendations